antiserum specific for rat ammopeptadase M has been used for the ammunohistochemlcal localizatmn of the enzyme m rat brain and peripheral tissues. The enzyme m brain is localized exclusively on blood vessels. Within the pituitary the enzyme was assocmted with the vasculature m the postermr lobe, on the surface of the mtermedmte lobe and on the surface of some cells in the anterior lobe In the laver, fine cell staining was observed between parenchymal cells, m the deum the entire lumenal surface was stained, whde m the kadney both proximal tubular and a central tubular stammg was detected In each tissue ammopepudase M as localized such that it can hmlt d~ffUSlOn across spemfic bamers Amlnopeptldase M activity m brain has been proposed to functmn in the degradation of synaptmally released enkephahns. Its localizatmn on blood vessels reqmres that enkephalms daffuse pnor to degradatmn, a concept not m concert w~th current hypotheses Based on these studies at is proposed that &ffusmn away from enkephahnerglc synapses plays a key role m terminating enkephalm action Amlnopept~dase M Immunoh~stochemlstry Enkephahn degradation m brain IT is currently beheved that the physiological action of synaptically released enkephalins is terminated by enzymatic degradation [12, 21, 22] . Two peptidase activities have been ~dentified in synaptic membrane preparations which could act as "enkephalinases" m vtvo. One of these is a neutral metalloendopeptidase which cleaves enkephalins at the Gly-Phe bond, while the other is an aminopeptidase which cleaves at the Tyr-Gly bond of the enkephalins [12, 21, 22] . Two membrane bound aminopeptldases were identified in rat synaptic membrane preparations and designated MI and MII [11, 13] . Aminopeptidase MII exhibits a broad substrate specifimty with regard to amino acid beta naphthylamides and has been shown to represent the major enkephalin degrading ammopeptidase activity in brain homogenates [11] . Its distribution in rat brain approximates the distribution of enkephalin receptors [13] . The enzyme is inhibited by the classmal aminopeptidase inhibitor bestatm but can be distingmshed from other membrane aminopept~dases by its sensitivlty to inhibition by puromycin [11, 13] .
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Although this enzyme appeared to represent the major aminopeptldase which could act as an "enkephalinase" in vivo, several studies have raised questions concerning the role of aminopeptldase MII in degrading synaptically released enkephalins. Using brain shces it was shown that individually the neutral endopeptidase inhibitor thiorphan and the general aminopeptidase inhibitor bestatin could protect endogenous enkephalins, released by potassium depolarization, against degradation [5, 6] . Together these inhibitors afforded almost complete protection against enkephalin degradation. In addition these mhibitors alone or m combination produced an analgesm effect m mice However, the aminopeptldase MII inhibitor puromycin, which is relatively specific for this enzyme, was ineffective in protecting synaptically released enkephalins from degradation and did not elicit an analgesic response in experimental ammals [3, 5, ~Requests for reprints should be addressed to Louts B. Hersh, Department of Biochemistry, The Umverslty of Texas Health Sc,ence Centre at Dallas, 5323 Harry Hines Blvd., Dallas, TX 75235 6] However in another study [10] puromycm produced a dose-related, naloxone reversible analgesia in rats which was accompanied by an increase in striatal enkephalin levels.
An apparent solution to this confusion was the recent finding of aminopeptidase M activity in rat brain synaptlc membrane preparations [8, 9, 17] . This enzyme was separated from aminopeptidase MII by either chromatography on conA-sepharose [8, 9] or by phase separation using Triton X-II4 [17] . Aminopeptidase M (APM) activity comprised approximately 5% of the total membrane aminopeptidase activity. The enzyme hydrolyzes enkephalins with a Km of 45 /~M It is potently inhibited by bestatm (KI=4/zM), but poorly inhibited by puromycin (Ki= 100/zM). By comparison aminopeptidase MII exhibits a Kl of 0.5/xM for bestatin and a KI of 1 /~M for puromycin. Both of these aminopeptidases can be distinguished from aminopeptidase MI [11] The latter enzyme is specific for basic aminoacld beta naphthylamldes, is considerably less sensitwe to puromycm (KI= 1 mM), and does not hydrolyze enkephalins at an appreciable rate [8] .
Thus if aminopeptldase M could be shown to exist at enkephalinerglc synapses or in the neuropile of enkephahn rich areas its involvement m the degradation of synaptically released enkephalins would be more firmly established. In the present paper we report the results of immunohlstochemIcal studies on the localization of ammopeptidase M m rat brain and selected peripheral tissues.
METHOD

Purifi~ atton oJ Ammopepttda~e M
Ammopeptldase M was purified from rat kidney using a modification of the procedure used by Gros et al. [8] . Rat kidneys were homogenized in 10 volumes of 50 mM Tris-HCl buffer, pH 7.5. The membrane fraction was obtained as described [8] and solubllized by resuspension in a volume of 50 mM Tns-HC1, pH 7.5 containing 1% Triton X-100 equal to the original weight of tissue. After stirring for 1 hour at room temperature, the material was centrifuged at 100,000 × g for 1 hour. To the 100,000 × g supernatant was added MgCI.,, MnCl2, and CaCI.., to a final concentration of 1 mM and 2-mercaptoethanol to a final concentration of 5 mM. The enzyme was then chromatographed on Con A-Sepharose and DEAE-cellulose as described by Gros et al. [8] Starting with 50 g or rat kidney 1.6 mg of essentially homogeneous enzyme was obtained.
A,s say of Aminopepttdase A~ ttvttv Aminopeptidase activity was measured with alanme beta-naphthylamide as substrate as previously described [13] . Reaction mixtures contained 0.2 mM alanlne betanaphthylamlde, 50 mM Tris-HC1 buffer, pH 7.4, and enzyme m a final volume of 250/zl. Protein was determined by the method of Bradford [1] .
Ammopepttda~e M Anttsera
The anti-rat kidney ammopeptidase M antisera used m these studies was that prepared by Tsao and Curthoys [24] and provided to us as a generous gift.
Immttnoht~ tochemt.s In
Amlnopeptldase M ,mmunohistochemistry was conducted by standard procedures [23] . Male Sprague-Dawley rats were either untreated or injected with colchicme (200
FIG 1 Immunoblot detection of rat kidney and rat brain amlnopeptldase M Ammopeptldase M from vanous samples of rat kidney or rat brain was subjected to SDS-PAGE and eaher sta,ned for protein with Coomassle Blue or electrophoretlcally transferred to mtrocellulo,se and vlsuahzed w~th antJ-ammopeptldase M antlsera The samples tested were as follows Lane 1--20/zg of crude rat kidney homogenate Lane 2--2 tzg of purified rat kzdney APM Lane 3--20 /zg of rat brain homogenate Lane 4--10 ~tg of rat brain ammopeptldase M eluted from con A-sepharose /xg/10 /zl of normal sahne) in the lateral ventricle. After 48 hours of colchlcine treatment the rats were perfused w~th 4%, neutral buffered formaldehyde. The brains were removed and postfixed for 1 hour in 4% formaldehyde, immersed m 15% sucrose overnight and then frozen in hquid nitrogen. The t~ssue was cryostat sectioned at 10 /zM and mounted onto gelatin subbed slides. Aminopeptzdase M antiserum was used at tlters ranging from 1/100 to 1/1,000 on whole coronal sections taken throughout rat brain. Sections were taken in a similar fashion from pituitary, ileum, kidney and liver Tissue sections were Incubated overnight at 4°C with the APM antisera, then washed in phosphate buffered saline (PBS). Goat anti rabbit serum was applied to the tissue and sections incubated overnight at 4°C The tmsue was washed in PBS, incubated at 37°C for 40 minutes with rabbit anti horseradish peroxldase (HRP), washed again m PBS and then incubated at 37°C for 40 minutes with 4 /zg/ml HRP enzyme. After completion of this step the slides were immersed m a solution of 0.125 mg/ml diaminobenmdine tetrahydrochlonde and 0.03% H202 for 15 minutes The tissue was then washed for 30 minutes m water immersed in 2% OsO4 briefly, dehydrated and mounted in Permount. Observations were made on a Leitz Orthoplan Microscope. Blocking competition studies, using purified rat kidney amlnopeptidase M enzyme (2.5 mg/ml), were carried out at two antiserum concentrations (1/100 and 1/1,000) and at several enzyme concentrations (12.5/.tg, 2.5 ttg, 0.5/zg, 0.25/zg, 0 025 /zg, per 100 ~1 Incubation volume). Thirty minutes prior to addition of serum to the section, enzyme solution was added to antiserum. A parallel control study with enzyme buffer only was carried out with the same volumes as the 12.5 ~g concentration of enzyme.
Other Method~
SDS-PAGE and immunoblot analysis was conducted as previously described [2] . recently been demonstrated by Gros et al. [8, 9] and by Matsas et al. [17] . We have confirmed this observation using Con A-Sepharose to resolve aminopeptidase M from aminopeptidase MII activity as described by Gros et al. [8] .
Aminopeptidases MI and MII do not bind to Con ASepharose, while amlnopeptidase M activity is retained by Con A-Sepharose and subsequently eluted with 0.2 M methyl alpha-D-mannoside. Approximately 3% of the total aminopeptldase activity obtained from a Triton extract of rat brain membranes is attributable to amlnopeptidase M activity when assayed with alanine beta-naphthylamide as a substrate. To confirm that the aminopeptidase activity bound to Con A-Sepharose is indeed aminopeptidase M, the ability of an anti-rat kidney aminopeptidase M antiserum to inhibit this activity was examined. This antisera showed essentially the identical inhibition curve with rat kidney aminopeptidase M as with the putative rat brain aminopeptidase M activity. No inhibition of aminopeptidase MII activity was observed with this antisera. Adsorption of the antisera with purified rat kidney aminopeptidase M abolished both the ability of the antisera to inhibit both the brain and kidney activities as well as the ability to visualize either protem by immunoblotting.
In addition 25/zM puromycln inhibited aminopeptidase MII activity more than 90% while aminopeptidase M activity was inhibited less than 20% at this concentration of puromycin. Both kidney and brain aminopeptldase M activities were inhibited greater than 90% with 15 /xM bestatin. These results serve to establish the identity of the kidney and brain aminopeptidase M. The speoficlty of the anti-aminopeptldase M antisera was exammed by immunoblot analysis. As shown in Fig. 1 this antiserum brads to only a single protein in a crude rat kidney homogenate which corresponds to the purified enzyme. The level of aminopeptidase activity in brain ~s too low to be detected in a crude homogenate by immunoblot analysis. However we were able to visualize a partially purified preparation of the rat brain enzyme. The absence of any detectable immunoreactivity with a crude rat brain homogenate as well as the finding that only amlnopeptldase M reacts with the antiserum in a crude kidney homogenate demonstrates that this antiserum is monospeclfiC for aminopeptidase M and exhibits no cross-reactivity with any proteins found in rat brain. Based on the above experiments this antiserum was judged suitable for immunohistochemical visualization of the enzyme in rat brain.
The anti aminopeptldase M antiserum stained rat brain at concentrations up to (1/1,000). At 1/100 the staining of brain was composed of three types of signals, modest nuclear and cytoplasmic stains throughout the neuropile, and a denser stain surrounding all blood vessels (Figs. 2 and 4) . There was no obvious preference of particular brain regions, as all seemed positive. At 1/1,000, only the vascular staining could be detected (Figs. 3 and 5 ). Because colchicine pretreatment was indistinguishable from untreated rats, all data are on normal, untreated rats.
Because it was unclear which of the staining patterns was specific (vascular, nuclear or cytoplasmic) we carried out solution-phase competition studies at 1/100 and at 1/1,000 antibody dilution. At 1/100 the enzyme buffer solution did not alter the staining patterns. However 12.5 ~zg of APM enzyme (and 2.5/xg of APM enzyme) completely blocked all vascular staining without obviously effectlng the nuclear and cytoplasmic staining (Figs. 2C and 4C ). At 0.5 p.g of APM enzyme, return of faint vascular staining was detected (Figs 2B and 4B), with increasingly clear staining as the concentration of antigen dropped (0.25 /zg, 0.025 ~g). At 1/1,000 tlter the buffer had no effect on the only staining in the section (around the vasculature). All staining was blocked at 12.5/~g, 2.5/xg and 0.5 p~g of APM enzyme (Figs. 3C and 5C ) beginning to return at 0.25/zg (Figs. 3B and 5B) and increasing as the antigen concentrahon dropped. Thus specific, blockable staining was only detected in the region of brain vasculature and not in the nuclei, cytoplasm or the neuroplle. Beyond the vasculature the other set of apparently stained structures included the chorold plexus, ependyma and dura. After blocking it became clear the choroid plexus was not specifically stained. However, both the dura and ependyma were only partially blocked suggesting the possibility of a modest amount of APM in those tissues.
The pituitary showed blockable staining in all three lobes at 1/1,000 tlter ( Fig. 6A and a) . In the posterior pituitary the staining again appeared to be associated with vasculature. In the intermediate lobe only its surface was immunopositive. Small regions of patchy lmmunoreactivity, apparently at the cell surface, were seen in the anterior lobe. In the liver fine cell surface staining could be detected between parenchymal cells (Fig. 6D ). In the rat ileum the entire lumen was positively stained over the surface of the villus projections (Fig.  6B ). In the kidney two specific staining patterns could be seen (Fig. 6C) . One is a very heavy proximal tubular stam and the second is a lighter more central tubular stain. No glomeruli were stained. In the adrenal medulla patches of APM were detected (Fig. 6E ) in the cortex a lower level of staining was also seen.
DISCUSSION
The results of these studies clearly demonstrate that aminopeptidase M activity in rat brain is localized primarily if not exclusively on blood vessels. Beyond this vascular pattern in the brain the localization of APM on proximal tubules in the kidney, between parenchymal cells of the liver, on some cell surfaces in the anterior pituitary and adrenal medulla, on the luminal surface of the small gut--all suggest a unique physiological role for APM. In each case this enzyme is localized so that it can limit diffusion of peptides across certain barriers. The broad substrate specificity of amlnopeptidase M is consistent with its role in hydrolyzing a broad spectrum of peptlde substrates which differ amongst different tissues. APM in brain vessels might limit contact between blood born materials and neurons; in kidney APM in the tubules may degrade peptides and thereby prevent their reentry into the vasculature. In the gut, APM on the surface of the lumen might also control access of consumed substances to the vasculature. In a similar fashion APM on liver parenchyma, adrenal medulla and anterior pituitary cell surface may help limit peptide diffusion through these sinusoidal systems. It should be noted that APM's vascular localization in other tissues has previously been demonstrated [19] .
Given this general distribution pattern, the evidence that aminopeptidase M acts as an "enkephahnase" in brain must be reconciled with its barrier type localization. It has been assumed that the analgesic effect of the aminopeptidase inhibitor bestatin is directly related to its inhibition of the enzyme [8, 9] . Inhibition of the enzyme would decrease the rate at which endogenously released enkephalins are inactivated. Enkephalin levels would mcrease, which in turn would lead to a greater occupancy of enkephalin receptors. Support for this hypothesis comes from the observation that 
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bestatin increases the level of intact enkephalin which can be recovered after potassium depolarization of brain slices [5, 6] or after substance P induced enkephalin release from rat spinal cord [4] . A tacit assumption of this model is that the enkephalin degrading peptidases which act as "enkephalinases" in vtvo are located at synaptlc clefts between enkephalinergic neurons analogous to the localization of acetylcholinesterase at cholinergic synapses.
The current light microscopic study offers little support for aminopeptidase M localization in the neuropfle and therefore does not support synaptm region localization. The heavily vascular localization in the brain reported here ~s a very broad CNS pattern and ~s not distributed in a fashion unique to OplOld receptors or enkephalin terminals. It has in fact been seen in all brain areas studied and has been shown to be an enzyme with rather broad peptide actions [19] . Thus the model that enkephalin degrading peptidases which act as "enkephalinases" m v~vo are located at enkephalinergic synapses is not supported by this study. Instead a model in which enkephalins diffuse away from enkephalinergic synapses and are then degraded distal to the receptor appears more consistent with our findings.
The neutral endopeptidase called "enkephalinase" has also been lmphcated as acting as an "enkephalinase" m vtvo [12, 21, 22] . This enzyme has recently been found to be localized on glial cells and not on neurons [15, 16] . Thus, like amlnopeptldase M, this enzyme could not easily exert its "enkephahnase" action directly at enkephallnergic synapses.
The question that remains to be answered is how the enkephalin degrading peptidases can act as "enkephalinases" in vtvo, and yet be located outside enkephallnerglc synapses. One possibility is that a minor fraction of these enzymes does in fact exist m the neuropile at enkephalinergm synapses. If only a small fraction of APM was located at enkephahn synapses it is unlikely that the current methods could detect it. Multiple forms of the neutral endopeptidase "enkephallnase" have been observed [7, 20] , and one of these subforms could represent a synapse specific form of the enzyme. However no such multiple forms of aminopeptidase M have been reported, and no evidence that the multiple "enkephalinase" forms have different cellular locahzatlon has been obtained.
A model that can be considered is one in which the levels of synaptically released enkephahns exceed that reqmred by the enkephalin receptors. Diffusion of free enkephalin away from the vlCinlty of its receptor might reduce its concentration below the Kd of the receptor. However, the extracellular space through which the enkephalins diffuse is of a limited finite volume. The concentration of free enkephalins would initially be rapidly decreased as they move through a large concentration gradient, but would remain relatively high as the concentration of free enkephalins distal to the receptor increases. The resultant effect would be a pool of free enkephallns which exists for a relatively large time in the vicinity of enkephahn receptors. However, if enkephalin degrading peptidases act m proximity to enkephalinergic synapses the diffusion of enkephalins away from their receptor would be facilitated by the maintenance of a large concentratlon gradient. The function of "enkephalinases" thus might be to maintain a concentration gradient to ensure the efficient diffusion of enkephalins away from their receptors.
The functioning of peptidases in this manner would explain how they serve as "enkephalinases" with their localization being distal to enkephalinerglc synapses. In addition, the lack of specificity known to exist in all of the peptidases believed to act as "enkephalinases" m vivo would not be inconsistent with such a model. The action of these peptldases distal to enkephahnerglc receptors would not require the high degree of specificity seen in an enzyme such as acetylcholinesterase, and would permit these peptidases to service a variety of peptiderglc systems. For example angiotensm converting enzyme [12, 21] and the enkephalln degrading aminopeptldases M and MII [14] hydrolyze opioid as well as non-opioid peptides. The neutral endopeptidase "enkephalinase" acts on a variety of opiold as well as nonoploid peptldes [14] and it has been proposed that this enzyme is the major substance P degrading peptldase in brain [18] .
Thus we propose that "enkephalinases" function not by reactivating enkephalins at enkephallnergic synapses, but rather in rough proximity to these synapses. The role of these peptldases may be to faclhtate the diffusion of enkephalins away from their receptors.
